Login to Your Account



Pharming regains U.S. rights to hereditary angioedema drug

By Nuala Moran
Staff Writer

Wednesday, August 10, 2016

LONDON – Pharming Group NV has seized on Valeant Pharmaceuticals Inc.'s need to "stabilize" its organization and streamline the portfolio, taking back all U.S. rights to Ruconest in the treatment of acute HAE.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription